CN110891938B - 四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂 - Google Patents
四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂 Download PDFInfo
- Publication number
- CN110891938B CN110891938B CN201880033700.7A CN201880033700A CN110891938B CN 110891938 B CN110891938 B CN 110891938B CN 201880033700 A CN201880033700 A CN 201880033700A CN 110891938 B CN110891938 B CN 110891938B
- Authority
- CN
- China
- Prior art keywords
- halogen
- substituted
- optionally substituted
- compound
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1704714.3 | 2017-03-24 | ||
| GBGB1704714.3A GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
| PCT/GB2018/000047 WO2018172727A1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110891938A CN110891938A (zh) | 2020-03-17 |
| CN110891938B true CN110891938B (zh) | 2023-10-31 |
Family
ID=58687800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880033700.7A Expired - Fee Related CN110891938B (zh) | 2017-03-24 | 2018-03-26 | 四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11220483B2 (https=) |
| EP (1) | EP3601229B1 (https=) |
| JP (1) | JP7099672B2 (https=) |
| KR (1) | KR102636166B1 (https=) |
| CN (1) | CN110891938B (https=) |
| AU (1) | AU2018238102B2 (https=) |
| BR (1) | BR112019019868A2 (https=) |
| CA (1) | CA3057415A1 (https=) |
| GB (1) | GB201704714D0 (https=) |
| MX (1) | MX394818B (https=) |
| WO (1) | WO2018172727A1 (https=) |
| ZA (1) | ZA201906873B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
| WO2022076503A1 (en) * | 2020-10-08 | 2022-04-14 | Eli Lilly And Company | 6-methoxy-3,4-dihydro-1h-isoquinoline compounds useful in the treatment of diabetes |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053446A2 (en) * | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| CN101663298A (zh) * | 2007-02-22 | 2010-03-03 | Irm责任有限公司 | 作为g蛋白偶联受体调节剂的噻唑衍生物 |
| EP2298750A1 (en) * | 2008-06-02 | 2011-03-23 | Msd K.K. | Novel isoxazole derivative |
| WO2016105118A2 (ko) * | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005282721A1 (en) * | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| AU2006279548A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| CA2627682A1 (en) | 2006-01-30 | 2007-08-09 | Irm Llc | Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators |
| EP2736330A4 (en) | 2011-07-29 | 2015-05-27 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
-
2017
- 2017-03-24 GB GBGB1704714.3A patent/GB201704714D0/en not_active Ceased
-
2018
- 2018-03-26 EP EP18715236.8A patent/EP3601229B1/en active Active
- 2018-03-26 AU AU2018238102A patent/AU2018238102B2/en active Active
- 2018-03-26 JP JP2020501850A patent/JP7099672B2/ja active Active
- 2018-03-26 WO PCT/GB2018/000047 patent/WO2018172727A1/en not_active Ceased
- 2018-03-26 CA CA3057415A patent/CA3057415A1/en active Pending
- 2018-03-26 CN CN201880033700.7A patent/CN110891938B/zh not_active Expired - Fee Related
- 2018-03-26 KR KR1020197031368A patent/KR102636166B1/ko active Active
- 2018-03-26 US US16/496,786 patent/US11220483B2/en active Active
- 2018-03-26 MX MX2019011314A patent/MX394818B/es unknown
- 2018-03-26 BR BR112019019868A patent/BR112019019868A2/pt not_active Application Discontinuation
-
2019
- 2019-10-18 ZA ZA2019/06873A patent/ZA201906873B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053446A2 (en) * | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| CN101663298A (zh) * | 2007-02-22 | 2010-03-03 | Irm责任有限公司 | 作为g蛋白偶联受体调节剂的噻唑衍生物 |
| EP2298750A1 (en) * | 2008-06-02 | 2011-03-23 | Msd K.K. | Novel isoxazole derivative |
| WO2016105118A2 (ko) * | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3057415A1 (en) | 2018-09-27 |
| AU2018238102A1 (en) | 2019-10-31 |
| AU2018238102B2 (en) | 2021-11-04 |
| KR102636166B1 (ko) | 2024-02-13 |
| JP7099672B2 (ja) | 2022-07-12 |
| JP2020515636A (ja) | 2020-05-28 |
| ZA201906873B (en) | 2022-03-30 |
| EP3601229B1 (en) | 2024-11-06 |
| US20200317619A1 (en) | 2020-10-08 |
| MX394818B (es) | 2025-03-24 |
| AU2018238102A2 (en) | 2019-11-07 |
| US11220483B2 (en) | 2022-01-11 |
| KR20190140936A (ko) | 2019-12-20 |
| RU2019133659A3 (https=) | 2021-07-16 |
| BR112019019868A2 (pt) | 2020-04-22 |
| GB201704714D0 (en) | 2017-05-10 |
| WO2018172727A1 (en) | 2018-09-27 |
| EP3601229A1 (en) | 2020-02-05 |
| MX2019011314A (es) | 2020-01-27 |
| CN110891938A (zh) | 2020-03-17 |
| RU2019133659A (ru) | 2021-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110891938B (zh) | 四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂 | |
| JP6832342B2 (ja) | 複素環化合物 | |
| JP4171700B2 (ja) | 複素環化合物および使用方法 | |
| JP6163695B2 (ja) | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 | |
| TWI330639B (en) | Oxazole compound and pharmaceutical composition | |
| KR20150118158A (ko) | 항당뇨병 비시클릭 화합물 | |
| CN114258390A (zh) | 用于疾病治疗的乙醇酸氧化酶抑制剂 | |
| WO2018006795A1 (zh) | 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用 | |
| CN116547270A (zh) | 4-(2-氟-4-甲氧基-5-3-(((1-甲基环丁基)甲基)氨基甲酰基)双环[2.2.1]庚-2-基)氨基甲酰基)苯氧基)-1-甲基环己烷-1-甲酸衍生物以及类似化合物作为rxfp1调节剂用于治疗心力衰竭 | |
| EP3177282A1 (en) | Antidiabetic bicyclic compounds | |
| WO2016022742A1 (en) | Antidiabetic bicyclic compounds | |
| KR20190034318A (ko) | Ido1억제제 및 이의 제조방법과 응용 | |
| CN115716827A (zh) | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 | |
| JP2011513232A (ja) | Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物 | |
| JP2017503760A (ja) | 新規インダニルオキシフェニルシクロプロパンカルボン酸 | |
| EA030561B1 (ru) | Тетразолон-замещенные дигидропиридиноновые ингибиторы mgat2 | |
| JP2023513373A (ja) | Ｐ２ｘ３修飾薬 | |
| TW202134248A (zh) | Sstr5拮抗劑 | |
| KR20210082466A (ko) | 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물 | |
| TW202233591A (zh) | 2-吡啶酮及其使用方法 | |
| US11905230B2 (en) | Phenoxyacetic acid derivatives, preparation method thereof and use thereof as medicament | |
| WO2010004198A2 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
| RU2776801C2 (ru) | Производные тетрагидробензо[d]азапена в качестве модуляторов as gpr120 | |
| KR20250004873A (ko) | Atp 시트레이트 리아제의 마크로시클릭 억제제 | |
| JP2024515985A (ja) | ６員芳香族ヘテロ尿素環の誘導体及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20231031 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |